ArticleProceedings (Baylor University. Medical Center)2025
Recombinant von Willebrand factor use in obstetric anesthesia.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery.Research and practice in thrombosis and haemostasis · 2026Observational
- Recombinant von Willebrand factor: a new tool to manage von Willebrand disease in obstetric patients.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In pregnant patients with von Willebrand disease who have reduced von Willebrand factor (VWF) activity but normal factor VIII activity, recombinant VWF may be considered to supplement VWF. Methods: All patients with known diagnosis of von Willebrand disease who were admitted for delivery and received recombinant VWF between October 2019 and March 2023 were included. Demographic data, peripartum course, laboratory data, neuraxial use, and bleeding complications were reviewed. Results: There were 8 deliveries in 6 patients who had von Willebrand disease and received recombinant VWF during the study period. All patients received neuraxial analgesia or anesthesia after administration of recombinant VWF without complications. No patient required additional recombinant VWF supplementation at delivery. Conclusion: Recombinant VWF may be an option for peripartum management in parturients with selective reduction in VWF activity and normal factor VIII activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.